Oxurion Announces Preclinical Presentation on THR-149 at KININ2022
07 Juin 2022 - 07:00PM
Leuven,
BELGIUM, Boston, MA, US
– JUNE 7,
2022 –
Oxurion NV (Euronext
Brussels: OXUR), a
clinical stage biopharmaceutical company developing next generation
standard of care ophthalmic therapies in patients with retinal
disorders including diabetic macular edema, today delivered a
preclinical presentation evaluating the pharmacokinetic properties
of THR-149 at KININ2022, held in Annecy, France, June 5-8,
2022.
The KININ2022 presentation is available under
Conferences and Events within the Investors section of the
Company’s website.
Overview: THR-149, a bicyclic
peptide identified by a combination of phage-based selections and
directed medicinal chemistry, is a potent and specific inhibitor of
plasma kallikrein. In preclinical studies, THR-149 effectively
blocked the release of bradykinin in the vitreous and reduced the
level of edema and retinal vascular leakage in rodent models.
Results: IVT-PK and IV-PK data
were analyzed based on a mono-compartmental pharmacokinetic model,
leading to ocular and systemic half-lives of 36 h and 1.1 h,
respectively. The model indicates IVT administration of THR-149
reduces the four DME disease hallmarks: retinal vascular leakage,
retinal edema, retinal inflammation and reactive gliosis.
THR-149 is being developed as a potential new
standard of care for the up to 50% of diabetic macular edema (DME)
patients showing suboptimal response to anti-VEGF therapy. Oxurion
is currently evaluating THR-149 for the treatment of DME in Part B,
the second part of its two-part Phase 2 KALAHARI trial.
About
OxurionOxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.For more information, please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel:
+32 16 75 13 10tom.graney@oxurion.com Michaël DillenChief
Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com |
USConway Communications Beth
Kurth bkurth@conwaycommsir.com Westwicke, an ICR
CompanyChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
- OXUR KININ Presentation 2022.0607
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024